Compare MCS & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCS | ETON |
|---|---|---|
| Founded | 1935 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.2M | 498.8M |
| IPO Year | N/A | 2018 |
| Metric | MCS | ETON |
|---|---|---|
| Price | $16.07 | $16.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $24.00 | ★ $29.67 |
| AVG Volume (30 Days) | 257.2K | ★ 272.1K |
| Earning Date | 10-31-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $712,239,000.00 | $70,316,000.00 |
| Revenue This Year | $10.32 | $113.27 |
| Revenue Next Year | $5.27 | $36.70 |
| P/E Ratio | $65.59 | ★ N/A |
| Revenue Growth | 6.27 | ★ 102.77 |
| 52 Week Low | $12.85 | $11.09 |
| 52 Week High | $22.55 | $23.00 |
| Indicator | MCS | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 60.44 | 48.52 |
| Support Level | $14.63 | $16.13 |
| Resistance Level | $15.79 | $17.05 |
| Average True Range (ATR) | 0.45 | 0.75 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 90.79 | 79.66 |
Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.